PYC Therapeutics (ASX:PYC) has announced that the Safety Review Committee governing the Phase 1 clinical trial of VP-001 being studied in Retinitis Pigmentosa type 11 has approved the escalation of dosing to patient cohort 3. …
PYC Therapeutics progressing to high dose patient cohort in RP11 trial
December 18, 2023 Australian Biotech
Latest Video
New Stories
-
Former Speaker of the House appointed as official Patron of Rare Cancers Australia
March 25, 2025 - - Latest News -
Another day, and another addition to what is now a motherload of bad ideas
March 25, 2025 - - Latest News -
Australian eye therapy company now focused on survival after clinical trial result
March 25, 2025 - - Latest News -
Mark Butler: Patients waiting too long and 'as the Health Minister, of course, I am sorry for that'
March 24, 2025 - - Latest News -
What happens to the conspiracy when the industry and ministerial criticisms sound remarkably similar?
March 24, 2025 - - Latest News -
Nanotechnology could improve odds in treating aggressive breast cancers
March 24, 2025 - - Latest News -
Call for safety net change with half a million Australians missing out on cheaper medicines
March 24, 2025 - - Latest News